Literature DB >> 9674746

Differential activity of P-glycoprotein in normal blood lymphocyte subsets.

C Ludescher1, G Pall, E U Irschick, G Gastl.   

Abstract

To better understand the phenomenon of P-glycoprotein (P-170) expression we investigated lymphocyte subpopulations for P-170 function in healthy volunteers. Studies were based on three-colour flow cytometry including the fluorescent probe rhodamine 123 (Rh123), which is transported by P-170. Marked Rh123 efflux was detected in CD8+ T lymphocytes with CD8+/CD45RA+ T cells (naive cells) showing significantly higher P-170 activity as compared with CD8+/CD45RA- cells (P<0.04). Vice versa, CD8+/CD45RO+ T cells (memory cells) demonstrated less P-170 activity than CD8+/CD45RO- cells (P<0.04). P-170 function was less prominent in CD4+ T cells, however, Rh123 efflux was higher in the CD4+/CD45RA+ and CD4+/CD45RO- subpopulations (P<0.025) corresponding to the CD8+ results. Dye efflux differed significantly between activated and non-activated CD8+ and CD4+ as well as CD8+/CD11b+ and CD8+/CD11b- T lymphocytes. Since CD16+ natural killer cells (NK) expressed the highest level of P-170, the NK cytotoxicity against 51Cr-labelled K562 target cells was assayed in the presence or absence of P-170 inhibitors. NK related cytotoxicity was significantly reduced in the presence of R-verapamil and dexnigaldipine-HCP in a dose-dependent manner. The differential expression of P-170 activity in naive and memory T cells together with the reduced NK related cytotoxicity in the presence of MDR-modulators suggest a physiological role of P-170 in immunological functions of these lymphocyte subsets. Consequently, the addition of MDR modulators to conventional chemotherapy as a strategy to overcome drug resistance should consider possible adverse immunosuppressive effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674746     DOI: 10.1046/j.1365-2141.1998.00751.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

Review 1.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.

Authors:  Soichi Haraguchi; Sarah K Ho; Matthew Morrow; Maureen M Goodenow; John W Sleasman
Journal:  J Leukoc Biol       Date:  2011-04-19       Impact factor: 4.962

3.  The human P-glycoprotein transporter enhances the type I interferon response to Listeria monocytogenes infection.

Authors:  Nadejda Sigal; Millie Kaplan Zeevi; Shiri Weinstein; Dan Peer; Anat A Herskovits
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

4.  Selective photodepletion of malignant T cells in extracorporeal photopheresis with selenorhodamine photosensitizers.

Authors:  Zachariah A McIver; Mark W Kryman; Young Choi; Benjamin N Coe; Gregory A Schamerhorn; Michelle K Linder; Kellie S Davies; Jacqueline E Hill; Geri A Sawada; Jason M Grayson; Michael R Detty
Journal:  Bioorg Med Chem       Date:  2016-06-02       Impact factor: 3.641

5.  Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem cell transplantations: T cell subset frequencies predict outcome.

Authors:  Zachariah A McIver; Jan J Melenhorst; Andrew Grim; Nicholas Naguib; Gerrit Weber; Vicki Fellowes; Hahn Khuu; David S Stroncek; Susan F Leitman; Minoo Battiwalla; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-30       Impact factor: 5.742

6.  Anti-AIDS agents 89. Identification of DCX derivatives as anti-HIV and chemosensitizing dual function agents to overcome P-gp-mediated drug resistance for AIDS therapy.

Authors:  Ting Zhou; Emika Ohkoshi; Qian Shi; Kenneth F Bastow; Kuo-Hsiung Lee
Journal:  Bioorg Med Chem Lett       Date:  2012-03-13       Impact factor: 2.823

7.  Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.

Authors:  Antonio Valentin; Matthew Morrow; Richard H Poirier; Karen Aleman; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

Review 8.  Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?

Authors:  G-T Ho; F M Moodie; J Satsangi
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

9.  New Verapamil Analogs Inhibit Intracellular Mycobacteria without Affecting the Functions of Mycobacterium-Specific T Cells.

Authors:  Getahun Abate; Peter G Ruminiski; Malkeet Kumar; Kawaljit Singh; Fahreta Hamzabegovic; Daniel F Hoft; Christopher S Eickhoff; Asmir Selimovic; Mary Campbell; Kelly Chibale
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

Review 10.  Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy.

Authors:  Kathleen Köck; Markus Grube; Gabriele Jedlitschky; Lena Oevermann; Werner Siegmund; Christoph A Ritter; Heyo K Kroemer
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.